Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3Thoracic 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Melanoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

trastuzumab deruxtecan 1trametinib 1spartalizumab 1ribociclib 1pexidartinib 1pembrolizumab 1dabrafenib 1Thalidomide 1Sunitinib 1Specimen Handling 1OSI 930 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Cetuximab 1Capecitabine 1CTLA-4 Antigen 17-hydroxystaurosporine 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × pexidartinib × Head & Neck × Clear all
NCT02452424 2020-03-05

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Daiichi Sankyo

Phase 1/2 Terminated
78 enrolled 19 charts
DermatologicGastrointestinalGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡